Buchanan Shareholder William A. Garvin Quoted in Bloomberg BNA Article on FDA’s Combo Products Report
A recent Food and Drug Administration report identifies a number of areas where the FDA could improve its combination product review process, according to a Bloomberg BNA article. Combination products – which are made up of combinations of a drug, device and/or bioglogical product – don’t fit in the traditional categories of drugs.
Buchanan FDA Shareholder William A. Garvin was quoted in the article, and told the publication that the report is a “good start” for the FDA. “Hopefully, the fact that Dr. Califf is involved with announcing these actions will ensure that if he becomes Commissioner, he will continue to make resolution of the combination products review issue a high priority,” Garvin said.
Read the full article – “FDA’s Combo Products Report Good First Step, Lawyers Say” (Bloomberg BNA, October 19, 2015) Subscription required.
Buchanan FDA Shareholder William A. Garvin was quoted in the article, and told the publication that the report is a “good start” for the FDA. “Hopefully, the fact that Dr. Califf is involved with announcing these actions will ensure that if he becomes Commissioner, he will continue to make resolution of the combination products review issue a high priority,” Garvin said.
Read the full article – “FDA’s Combo Products Report Good First Step, Lawyers Say” (Bloomberg BNA, October 19, 2015) Subscription required.
Contributors
Related Services & Industries
- AFFORDABLE HOUSING
- ANTITRUST & TRADE REGULATION
- APPELLATE
- ATTORNEY UPDATE
- AUTONOMOUS & CONNECTED VEHICLES
- BANKRUPTCY & CREDITORS' RIGHTS
- BUCHANAN IP GUEST ASSOCIATE PROGRAM
- CANNABIS
- CLASS ACTIONS
- COAL
- COMBINED HEAT & POWER (CHP)
- COMMERCIAL CONTRACTS
- COMMERCIAL FINANCE
- CONSTRUCTION
- CONSUMER DEFENSE
- CONSUMER PRODUCTS
- CONTACT INFORMATION
- CONVERGENCE: M&A INSIGHTS IN HEALTHCARE
- COPYRIGHT
- CORONAVIRUS (COVID-19)
- CORPORATE
- CORPORATE COMPLIANCE
- CORPORATE TAX
- CRIMINAL DEFENSE & GOVERNMENT ENFORCEMENT
- CYBERSECURITY & DATA PRIVACY
- E-DISCOVERY
- EDUCATION
- EMERGING COMPANIES
- EMPLOYEE BENEFITS & ERISA
- EMPLOYMENT LITIGATION
- ENERGY
- ENTERTAINMENT, MEDIA & SPORTS
- ENVIRONMENTAL
- ESTATES & TRUSTS
- EXECUTIVE COMPENSATION
- FAMILY OFFICE
- FDA & BIOTECHNOLOGY
- FINANCE
- FRANCHISE & DISTRIBUTION
- GOVERNMENT RELATIONS & PUBLIC POLICY
- HEALTHCARE
- HEALTHCARE ADMINISTRATIVE & JUDICIAL PROCEEDINGS
- HEALTHCARE INFORMATION SECURITY & PRIVACY
- HEALTHCARE LITIGATION
- HEALTHCARE REGULATORY & COMPLIANCE
- HEALTHCARE TRANSACTIONS
- HOSPITALITY
- HR & EMPLOYEE RELATIONS ISSUES
- IMMIGRATION
- INNOVATIVE HEALTHCARE DELIVERY & PAYMENT
- INSIDER INSIGHTS:
100 DAYS OF BIDEN - INSURANCE & REINSURANCE
- INTELLECTUAL PROPERTY
- INTERNAL INVESTIGATIONS
- INTERNATIONAL SERVICES
- INTERNATIONAL TAX
- IP LITIGATION
- LABOR & EMPLOYMENT
- LIFE SCIENCES
- LITIGATION
- MANUFACTURING
- MARITIME & ADMIRALTY
- MATRIMONIAL & FAMILY LAW
- MERGERS & ACQUISITIONS
- NONPROFIT ORGANIZATIONS
- OIL & GAS
- OPPORTUNITY ZONES
- PASS-THROUGH ENTITIES
- PATENT COUNSELING & STRATEGIC ADVICE
- PATENT OFFICE LITIGATION
- PATENT PROCUREMENT
- POST-ACUTE & LONG-TERM CARE
- POWER GENERATION & UTILITY
- PRODUCTS LIABILITY
- PUBLIC FINANCE
- PUBLIC PROCUREMENT & BID PROTESTS
- REAL ESTATE
- REAL ESTATE FINANCE
- REAL ESTATE TRANSACTIONS
- REIMBURSEMENT & MANAGED CARE
- RENEWABLES
- SECURITIES & SEC
- SECURITY ALARM
- SPORTS
- STATE & LOCAL TAX
- TAX
- TAX CONTROVERSY
- TECHNOLOGY TRANSACTIONS
- TRADE SECRETS & RESTRICTIVE COVENANTS
- TRADEMARK
- TRADITIONAL LABOR RELATIONS
- TRANSPORTATION
- VENTURE CAPITAL & PRIVATE EQUITY
- WATER
- WEALTH & SUCCESSION PLANNING
- WHITE COLLAR DEFENSE, COMPLIANCE & INVESTIGATIONS
- WORKPLACE SAFETY & HEALTH (OSHA & MSHA)
Related Offices